No quarterly revenue total was found in Calidi Biotherapeutics, Inc.'s SEC filings.
Calidi Biotherapeutics, Inc. (CLDI) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances). As of Jun 30, 2026 it held $4.1 million in cash and investments and $1.9 million in total debt.
Revenue
—
Net income
$-4.16M
+27.2% vs year-ago quarter
Operating cash flow
$-4.35M
+10.8% vs year-ago quarter
Free cash flow
—
EPS
$-2.94
+90.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
2.58M
-24.6% vs year-ago quarter
Net cash
$2.13M
Q2 FY2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- CLDI (NYSE), CLDWW (OTC)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1855485
- Former names
- Calidi Biotherapeutics, Inc. (until Sep 25, 2026); First Light Acquisition Group, Inc. (until Sep 19, 2023)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Operating income | -$4.2M | -$4.2M | -$4.5M | -$5.0M | -$5.7M |
| Net income | -$4.2M | -$4.1M | -$4.1M | -$5.1M | -$5.7M |
| Diluted EPS | -$2.94 | -$0.43 | -$572.79 | -$2.21 | -$31.75 |
| Operating cash flow | -$4.4M | -$4.1M | -$5.0M | -$4.2M | -$4.9M |
| Total assets | $7.2M | $9.6M | $8.9M | $14.0M | $9.4M |
| Total liabilities | $4.1M | $4.7M | $5.1M | $6.8M | $7.3M |
| Stockholders' equity | $3.1M | $4.9M | $3.8M | $6.9M | $1.8M |
| Cash and investments | $4.1M | $6.6M | $5.6M | $10.4M | $5.3M |
| Total debt | $1.9M | $2.3M | $2.6M | $2.9M | $3.5M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Listing notice, Other events
|
Sep 25, 2026 | Sep 21, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Sep 22, 2026 | Sep 17, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Change to shareholder rights, Bylaw or fiscal year change
|
Jul 31, 2026 | Jul 27, 2026 |
| 8-K |
Current report
Material agreement, Agreement ended, New debt
|
Jul 16, 2026 | Jul 10, 2026 |
All 406 Calidi Biotherapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.